NCT00092482View on ClinicalTrials.gov

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

PHASE3CompletedINTERVENTIONAL

Enrollment

3,882

Participants

Timeline

Start Date

June 28, 2002

Primary Completion Date

June 30, 2004

Study Completion Date

August 15, 2008

Conditions

Cervical CancerGenital Warts

Interventions

BIOLOGICAL

V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00092482 - Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | Biotech Hunter | Biotech Hunter